Comparative gastrointestinal blood loss associated with placebo, aspirin, and nabumetone as assessed by radiochromium (51Cr).
Nabumetone differs from most other nonsteroidal anti-inflammatory drugs. It is presented to the gut as a nonacidic prodrug, and is metabolized to its active form after absorption. Studies in animals and humans suggest it is less irritating to the gastrointestinal mucosa. This study compared the gastrointestinal microbleeding induced by nabumetone to aspirin (acetylsalicylic acid, ASA), and placebo in a double blind parallel study using chromium 51Cr labelled red cells to quantitate fecal blood loss (FBL) in healthy volunteers. Thirty subjects were randomized to treatment with nabumetone (2000 mg), ASA (3.6 g) or placebo for 21 days following a 7 day placebo period. Six subjects served as untreated controls. FBL in nabumetone treated subjects was not significantly different to placebo or untreated subjects. In contrast, ASA-treated subjects exhibited significantly increased FBL than the other 3 groups (P less than .0001).
Lussier
A
A
Faculty of Medicine, University of Sherbrooke, Quebec, Canada.
Davis
A
A
Lussier
Y
Y
Lebel
E
E
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001241:Aspirin / Q000009:adverse effects*; D002074:Butanones / Q000009:adverse effects*; D002860:Chromium Radioisotopes; D004311:Double-Blind Method; D005753:Gastric Mucosa / Q000187:drug effects; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects; D008297:Male; D000077430:Nabumetone; D011897:Random Allocation
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D002860:Chromium Radioisotopes; D000077430:Nabumetone; D001241:Aspirin